CytomX promotes Amy Peterson to President and COO; salary, equity grants disclosed

CytomX Therapeutics, Inc.

Dr. Peterson promoted to President and COO effective Feb 2, 2022; previously EVP & Chief Dev. Officer.
Annual base salary increased to $550,000; discretionary annual bonus target set at 50% of salary.
Received option for 200,000 shares at $4.13 strike price and 40,000 restricted stock units.
Dr. Sean McCarthy continues as Chairman and CEO; Peterson assumes President role formerly held by McCarthy.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Sean McCarthy

Chairman and Chief Executive Officer

CTMX · CytomX Therapeutics, Inc.

Effective: 2022-02-02
Filed: February 7, 2022, 6:59 PM ET

Dr. Sean McCarthy will continue in his positions as Chairman and Chief Executive Officer of the Company, while Dr. Peterson assumes the title of President previously held by Dr. McCarthy.

Role change

Amy Peterson

President and Chief Operating Officer

CTMX · CytomX Therapeutics, Inc.

Effective: 2022-02-02
Filed: February 7, 2022, 6:59 PM ET

On February 2, 2022, the Board of Directors of CytomX Therapeutics, Inc. (the “Company”) promoted Dr. Amy Peterson to serve as President and Chief Operating Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.85

Sean McCarthy changed role as Chairman and Chief Executive Officer at CytomX Therapeutics, Inc..

Role: Chairman and Chief Executive Officer

Exact text from the filing

Dr. Sean McCarthy will continue in his positions as Chairman and Chief Executive Officer of the Company, while Dr. Peterson assumes the title of President previously held by Dr. McCarthy.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Amy Peterson changed role as President and Chief Operating Officer at CytomX Therapeutics, Inc..

Action: promoted
Role: President and Chief Operating Officer

Exact text from the filing

On February 2, 2022, the Board of Directors of CytomX Therapeutics, Inc. (the “Company”) promoted Dr. Amy Peterson to serve as President and Chief Operating Officer of the Company.

View on SEC.gov

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-029142

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.